Loading...
•
Sep 30, 2023
Alkermes Q3 2023 Earnings Report
Alkermes reported solid financial results for Q3 2023, driven by revenue growth and strategic capital allocation.
Key Takeaways
Alkermes reported Q3 2023 financial results with total revenues of $380.9 million and GAAP net income of $47.8 million. Net sales of proprietary products increased approximately 16% year-over-year. The company reiterated its financial expectations for full-year 2023 and expects to complete the separation of its oncology business in November 2023.
Total revenues for the quarter were $380.9 million.
Net sales of proprietary products increased approximately 16% year-over-year to $231.8 million.
GAAP net income was $47.8 million, or $0.28 per diluted share.
The company expects to complete the separation of its oncology business in November 2023.
Alkermes
Alkermes
Alkermes Revenue by Segment
Revenue by Segment
VIVITROL Net Sales Revenue
CapyFin.comARISTADA Net Sales Revenue
CapyFin.comLYBALVI Net Sales Revenue
CapyFin.com Forward Guidance
Alkermes reiterated its financial expectations for full-year 2023, as set forth in its press release dated June 6, 2023.
Revenue & Expenses
Visualization of income flow from segment revenue to net income